Compare Stocks: CBWTF, NRC, and SPHRY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBWTF Cannabis Wheaton Income	$2.39 +1.1%	$2.16	$1.06 ▼ $2.66	$246.92M	1.38	24,901 shs	36,151 shs
NRC National Research	$21.93 +2.6%	$21.10	$11.32 ▼ $23.68	$498.82M	0.25	91,834 shs	91,299 shs
SPHRY Starpharma	$3.50	$5.25	$2.00 ▼ $5.98	$167.91M	1.31	1,638 shs	N/A

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBWTF Cannabis Wheaton Income	0.00%	-0.54%	-4.89%	+1,716.19%	+2,356.42%
NRC National Research	0.00%	+8.83%	+7.76%	+4.23%	+84.29%
SPHRY Starpharma	0.00%	-32.69%	-32.43%	-24.18%	+100.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBWTF Cannabis Wheaton Income	$2.39 +1.1%	$2.16	$1.06 ▼ $2.66	$246.92M	1.38	24,901 shs	36,151 shs
NRC National Research	$21.93 +2.6%	$21.10	$11.32 ▼ $23.68	$498.82M	0.25	91,834 shs	91,299 shs
SPHRY Starpharma	$3.50	$5.25	$2.00 ▼ $5.98	$167.91M	1.31	1,638 shs	N/A

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBWTF Cannabis Wheaton Income	0.00%	-0.54%	-4.89%	+1,716.19%	+2,356.42%
NRC National Research	0.00%	+8.83%	+7.76%	+4.23%	+84.29%
SPHRY Starpharma	0.00%	-32.69%	-32.43%	-24.18%	+100.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBWTF Cannabis Wheaton Income	0.00	N/A	N/A	N/A
NRC National Research	2.00	Hold	$26.00	18.56% Upside
SPHRY Starpharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CBWTF, NRC, and SPHRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	NRC National Research	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C-) ➝ Sell (D+)
10/5/2026	NRC National Research	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
8/21/2026	NRC National Research	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D+) ➝ Hold (C-)
8/6/2026	NRC National Research	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C-) ➝ Sell (D+)
7/29/2026	NRC National Research	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Market Outperform	$23.00 ➝ $26.00

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBWTF Cannabis Wheaton Income	$108.41M	2.28	$0.39 per share	6.12	$1.30 per share	1.84
NRC National Research	$137.39M	3.63	$1.26 per share	17.44	$0.62 per share	35.37
SPHRY Starpharma	$8.18M	20.53	N/A	N/A	$0.22 per share	15.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBWTF Cannabis Wheaton Income	$29.96M	$0.19	12.58	N/A	N/A	19.74%	18.36%	11.84%	N/A
NRC National Research	$11.60M	$0.25	87.72	20.89	N/A	4.18%	164.26%	14.67%	10/26/2026 (Estimated)
SPHRY Starpharma	-$5.07M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CBWTF, NRC, and SPHRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/26/2026	Q3 2026	NRC National Research	$0.21	N/A	N/A	N/A	$35.80 million	N/A
8/13/2026	Q2 2026	CBWTF Cannabis Wheaton Income	N/A	$0.05	N/A	$0.05	N/A	N/A
7/28/2026	Q2 2026	NRC National Research	-$0.15	$0.31	+$0.46	-$0.15	$34.90 million	$35.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBWTF Cannabis Wheaton Income	N/A	N/A	N/A	N/A	N/A
NRC National Research	$0.64	2.92%	+19.88%	256.00%	N/A
SPHRY Starpharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBWTF Cannabis Wheaton Income	0.21	2.23	1.35
NRC National Research	13.13	0.65	0.65
SPHRY Starpharma	N/A	3.40	3.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBWTF Cannabis Wheaton Income	N/A
NRC National Research	47.26%
SPHRY Starpharma	N/A

Insider Ownership

Company	Insider Ownership
CBWTF Cannabis Wheaton Income	4.60%
NRC National Research	9.20%
SPHRY Starpharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBWTF Cannabis Wheaton Income	446	103.31 million	98.56 million	Not Optionable
NRC National Research	357	22.75 million	20.65 million	Optionable
SPHRY Starpharma	45	47.97 million	N/A	Not Optionable

CBWTF, NRC, and SPHRY Headlines

Recent News About These Companies

Starpharma Holdings Limited - depositary receipt price target increased by 59.26% to $9.02

October 23 at 11:55 AM | msn.com

Starpharma Holdings Ltd ADR (SPHRY)

October 21, 2026 | investing.com

Starpharma CEO speaks with Proactive at the ASX SMIDcaps Conference

September 24, 2026 | finance.yahoo.com

Starpharma Holdings Ltd ADR SPHRY

May 7, 2026 | morningstar.comM

Starpharma enters collaboration, license agreement with Genentech

September 22, 2025 | msn.com

Starpharma Announces a Collaboration and License Agreement with Genentech

September 22, 2025 | markets.businessinsider.com

SPHRY Starpharma Holdings Limited

June 19, 2025 | seekingalpha.com

Change in Substantial Holder’s Voting Power at Starpharma Holdings

June 3, 2025 | tipranks.com

Pleasing Signs As A Number Of Insiders Buy Starpharma Holdings Stock

May 5, 2025 | uk.finance.yahoo.com

Starpharma Advances Strategic Initiatives and Expands Market Presence

April 29, 2025 | tipranks.com

Is Starpharma Holdings (ASX:SPL) In A Good Position To Deliver On Growth Plans?

March 25, 2025 | finance.yahoo.com

Robmar Investments Acquires Substantial Stake in Starpharma Holdings

March 17, 2025 | tipranks.com

Starpharma Highlights DEP® Dendrimer Platform at PepTalk Conference

January 15, 2025 | tipranks.com

Astodrimer by Starpharma for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Starpharma CEO Receives Major Performance Rights Issuance

December 12, 2024 | markets.businessinsider.com

Starpharma Issues Unquoted Securities to Boost Employee Incentives

December 12, 2024 | markets.businessinsider.com

Starpharma Holdings Reports Successful AGM Results

November 29, 2024 | tipranks.com

Starpharma Holdings Schedules Reconvened AGM for Key Vote

November 26, 2024 | tipranks.com

Starpharma AGM Results Highlight Voting Challenges

November 26, 2024 | tipranks.com

Starpharma Holdings Highlights Strategic Advances in 2024

November 25, 2024 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBWTF, NRC, and SPHRY Company Descriptions

Cannabis Wheaton Income OTCMKTS:CBWTF

$2.39 +0.03 (+1.06%)

As of 10/23/2026 03:55 PM Eastern

Auxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.

National Research NASDAQ:NRC

$21.93 +0.55 (+2.57%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$21.94 +0.02 (+0.07%)

As of 10/23/2026 07:30 PM Eastern

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Starpharma OTCMKTS:SPHRY

$3.50 0.00 (0.00%)

As of 10/23/2026

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CBWTF, NRC, and SPHRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CBWTF, NRC, and SPHRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CBWTF, NRC, and SPHRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBWTF, NRC, and SPHRY Company Descriptions

Cannabis Wheaton Income OTCMKTS:CBWTF

National Research NASDAQ:NRC

Starpharma OTCMKTS:SPHRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CBWTF, NRC, and SPHRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CBWTF, NRC, and SPHRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CBWTF, NRC, and SPHRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBWTF, NRC, and SPHRY Company Descriptions

Cannabis Wheaton Income OTCMKTS:CBWTF

National Research NASDAQ:NRC

Starpharma OTCMKTS:SPHRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools